

Thursday, 20 May 2021

## CONFIRMATION OF DISPATCH OF HOLDING STATEMENTS

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) advises that it has today dispatched holding statements in respect of its recently completed offer of shares under the prospectus lodged by ACL and ACL SaleCo Limited with the Australian Securities and Investments Commission on Wednesday, 28 April 2021 (**Offer**).

There were no refunds applicable for the Offer.

ACL's share register is managed by Link Market Services Limited (**Link**). Shareholders can contact Link with any questions regarding their shareholding on 1300 554 474 (toll free within Australia) or +61 1300 554 474 (outside Australia) between 8:30am and 7:30pm (Sydney time), Monday to Friday (excluding public holidays).

– ENDS –

This announcement was authorised for release to ASX by Eleanor Padman, Company Secretary. For further information regarding this announcement, please contact:

### Company Secretary

Eleanor Padman  
Company Secretary  
Email: [Eleanor.Padman@clinicallabs.com.au](mailto:Eleanor.Padman@clinicallabs.com.au)  
Phone: +61 422 002 918

### Investor Relations

Nick Taylor  
Investor Relations  
Email: [Nick.Taylor@clinicallabs.com.au](mailto:Nick.Taylor@clinicallabs.com.au)  
Phone: +61 409 194 243

### About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our 86 NATA accredited laboratories perform over 8 million episodes each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.